Wire · operational-macro
J&J files sNDA for Caplyta in bipolar I mania as fifth potential indication
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Johnson & Johnson has submitted a supplemental New Drug Application to the US FDA seeking approval for Caplyta to treat adult manic or mixed bipolar I episodes, potentially adding a fifth approved indication for the drug.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 11 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
You face a new competitor in bipolar mania treatment with J&J pushing Caplyta's approval ahead of Vanda's Bysanti. This could reshape market dynamics and create urgency for differentiation or partnerships in mood disorder therapies.
◆ Coverage
1 source · first reported 11 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics